Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Core Insights - Science 37 has successfully enhanced patient access to clinical trials through a partnership with a biopharmaceutical company focused on infectious disease prevention research, specifically in recruiting an immunocompromised patient cohort for a Phase 3 trial [1][2]. Patient Recruitment and Enrollment - Utilizing its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically qualified, and enrolled 129 patients across 36 states within an 8-week period, averaging 65 patients per month [2]. - As the top-enrolling site, Science 37 randomized and treated 42% of the patient cohort, achieving significant geographic, socio-economic, and cultural diversity among participants [2]. Challenges and Solutions - The complexity of certain studies makes recruitment and enrollment inherently challenging, particularly for rare conditions or sensitive patient populations, highlighting Science 37's capability to meet demanding clinical trial requirements while improving access for vulnerable groups in a decentralized manner [3]. - Science 37 offers its Patient Recruitment services on a standalone basis or in combination with its flagship Virtual Site, the Metasite™, to enhance patient enrollment efforts [3]. Company Overview - Science 37's mission is to accelerate clinical research by providing universal trial access for patients, utilizing solutions like the Metasite™ and Patient Recruitment to expand the reach of clinical trials beyond traditional sites [4]. - The company's proprietary technology stack, along with in-house medical and operational experts, enhances quality through standardized workflows and best-in-class study orchestration [4].